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Nocturia is a common symptom in both men and women. It can be troublesome by 
itself by disturbing sleep and can have a significant impact on the quality of sleep 
and the quality of life. In men, nocturia is often ascribed to prostatic disease without 
due consideration of other causes. However, other factors or a combination of fac-
tors are just as likely to be the cause. The cause of nocturia can usually be deter-
mined by a simple assessment of a patient’s history, an examination, and a voiding 
diary, plus a urodynamic study if necessary. Lifestyle and behavioral changes may 
benefit some individuals, but for many people, the only treatment option is phar-
macology. Antimuscarinic agents are the most common therapies for an overactive 
bladder and are often used to manage nocturia. The vasopressin analog desmo-
pressin consistently leads to improvement in nocturnal episodes of patients with 
proven polyuria. The risk of adverse events associated with most available medica-
tions requires careful monitoring to optimize better safety and tolerability.
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There are 2 CME questions based on this article
1. Introduction
Voiding at night, or nocturia, is not a recent problem. 
However, an aging population and recent innovations in 
treatment have brought more attention to this disorder. 
The International Continence Society (ICS) defines noc-
turia as, “the complaint that the individual has to wake 
at night one or more times to void”.1,2 This definition ex-
cludes nocturnal convenience voids, i.e., when the sub-
ject voids after having woken up for a different reason. 
Most related studies published prior to that nomencla-
ture report, and even many studies reported afterwards, 
did not strictly adhere to this definition when reporting 
the prevalence, consequence, and treatment of nocturia. 
The ICS defines the nocturnal urine volume as, “the total 
volume of urine passed between the time the individual 
goes to bed with the intention of sleeping and the time of 
waking with the intention of rising.” Therefore, nocturnal 
urine volume does not include the last void before going 
to bed, but it does include the first morning void.
There is no known reason why a healthy, elderly per-
son should suffer from nocturia. Nocturia can result 
from a broad range of urological and non-urological con-
ditions, and in any given individual, multiple conditions 
may coexist. Nocturia can also result from a number of 
pathological conditions, including cardiovascular dis-
ease, fluid redistribution, diabetes mellitus or insipidus 
(DI), lower urinary tract obstruction, and obstructive 
sleep apnea. Pathological changes in blood pressure, 
plasma urine electrolyte gradients, osmolarity gradi-
ents, plasma calcium, and glucose are strongly related 
to nocturia. In the elderly, the condition is often multi-
factorial. This article reviews the prevalence of nocturia, 
its medical impacts, its urological and non-urological 
causes, and possible strategies for its management by 
urologists.
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2. Prevalence
It is difficult to determine the exact prevalence of noctu-
ria because epidemiological studies vary in their defini-
tion of the condition. Prevalence increases with age, and 
therefore, most men and women over 80 years old will 
rise at least once at night to empty their bladder.3–5 The 
amount of data available on the frequency of voiding and 
the volume voided nocturnally across all age groups are 
also limited.
The prevalence of nocturia in community-dwelling 
populations is typically present in > 50% of both men 
and women older than 60 years. One survey, based on 
the definition by the ICS, yielded nocturia prevalence 
rates of 9–14% in the general adult male population, 
and considerably higher rates were found in the elderly 
and men with lower urinary tract symptoms suggestive 
of benign prostate hyperplasia.6
No large differences have been observed in the prev-
alence of nocturia between men and women; however, 
there is a tendency for young women to have this symp-
tom more often than young men, and for very old men 
to have it more often than very old women.7
3. Impact of Nocturia
Nocturia is relatively common among the elderly and 
becomes increasingly prevalent with age with profound 
influences on the quality of life (QoL), quality of sleep, 
daytime function, morbidity, and even mortality. Inter-
estingly, nocturia is regarded as the most bothersome 
urological symptom, not only by the afflicted but also by 
their partners.8,9
It is generally accepted that adults require 7–8 hours 
of sleep per night to refresh and restore the body. 
Nocturia is a major cause of sleep disturbance in people 
over 50 years of age.10 More than 60% of men and 
women have reported that nocturia has a negative ef-
fect on their QoL and quality of sleep.7 In addition to an 
increase in daytime fatigue and impaired performance, 
sleep disruption may also result in more-serious conse-
quences, such as immunosuppression, depression, and 
endocrine and metabolic alterations, which can affect 
motivation and job performance.
There is also an increased likelihood of traumatic 
fractures from falling when making trips to the toilet. 
A study of 1500 older ambulatory patients (with a mean 
age of 80 years) found that individuals voiding two or 
more times per night were significantly more likely to 
fall than those who did not void at night (odds ratio 
[OR], 1.84; p = 0.03). Another study found that the likeli-
hood of falling increased among patients who voided 
three or more times a night (OR, 2.15; p = 0.04).11
Taken together, those data show that the presence 
of nocturia, particularly when involving two or more epi-
sodes per night, has a major impact on the well-being of 
patients and may be associated with considerable mor-
bidity and even mortality.12
A recently developed nocturia QoL questionnaire 
measurement tool consists of 13 items assessing the 
productivity, level of activity impairment, energy, fa-
tigue, and level of concern. The score is able to discrimi-
nate between men suffering from one, two, or more 
episodes of nocturia, but it is has not been validated for 
use in women.13
4. Pathophysiology of Nocturia
The causes of nocturia fall into four categories: diurnal 
polyuria, nocturnal polyuria, decreased bladder capac-
ity, and mixed nocturia.
4.1. Diurnal polyuria
Diurnal polyuria is defined as an output of more than 
40 mL of urine per kg of body weight over a 24-hour 
period.14 As a result, polyuria is usually associated with 
increased urinary frequency during both daytime and 
nighttime. The common causes of diurnal polyuria are 
diabetes mellitus and DI of both central and nephro-
genic origins. Central DI is caused by the deficient syn-
thesis of the antidiuretic hormone, arginine vasopressin 
(AVP), secondary to the loss of neurosecretory neurons 
in the hypothalamus or posterior hypophysis. Central DI 
can usually be treated with desmopressin.16
Nephrogenic DI occurs when the kidneys fail to re-
spond to antidiuretic hormones, which could be a result of 
renal AVP resistance. Renal AVP resistance can be due to 
multiple mutations of the AVP receptor, which cause var-
ious degrees of receptor dysfunction.15 Nephrogenic DI 
can be treated with appropriate regulation of fluid intake. 
In addition, polydipsia, which may be either disogenic or 
psychogenic, can increase the total daily urine volume.
4.2. Nocturnal polyuria
Two key hormones regulating fluid homeostasis are 
AVP17 and atrial natriuretic peptide (ANP).18 AVP is 
secreted from the pituitary gland and acts on distal 
tubules and collecting ducts to promote water reabsorp-
tion. ANP is typically secreted from the atria of the heart 
in response to fluid overload and promotes water and 
sodium excretion by the kidneys. Pathophysiological 
changes due to these two hormones may lead to noctur-
nal polyuria.
Nocturnal polyuria is defined as an increase in night-
time urine production with a corresponding decrease in 
daytime urine production, resulting in a normal 24-hour 
urine volume. Although its precise definition remains 
somewhat flexible, an approximate description of noc-
turnal polyuria from the ICS is a nocturnal urine volume 
at least one third that of the total daily urine production.14 
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The formula for calculating the nocturnal poly uria index 
is simply the nocturnal urine volume divided by the 
24-hour urine volume. If 24-hour urine production is 
within normal limits, a nocturnal polyuria index of > 35% 
indicates nocturnal polyuria.18
Nocturnal polyuria was found to be the sole etiology 
for nocturia in 33% of patients and it was a combined 
etiology in 54.2% of patients.19 Nocturnal polyuria re-
sults from a disordered diurnal rhythm of sodium re-
creation and other unknown factors causing nocturnal 
urinary dilution.20 Compared with normal controls, noc-
turia patients have no diurnal variations in urine output 
and greater nocturnal urine production, which are asso-
ciated with a lack of a nocturnal increase in AVP levels.
Other causes of nocturnal polyuria include conges-
tive heart failure, diabetes mellitus, peripheral edema 
due to venous stasis or lymphostasis, nephritic syn-
drome, hepatic failure, and hypoalbuminemia, or life-
style patterns such as excessive nighttime drinking and 
a high intake of salt. Respiratory conditions, such as sleep 
apnea, may also cause nocturnal polyuria. Hypoxia in 
the lungs can lead to pulmonary vasoconstriction and 
a higher concentration of ANP, which is responsible for 
the elimination of sodium in the urine. This can result in 
nocturnal polyuria while the patient is sleeping.21
4.3. Decreased nocturnal bladder capacity (NBC)
A decreased NBC was found to be the sole etiology for 
nocturia in 16.2% of patients and it was a combined eti-
ology in 37.4% of patients.19 NBC is defined as the larg-
est voided volume during the hours of sleep. A lower 
NBC is related to a decreased maximum voided vol-
ume.21 Storage problems may also arise through blad-
der irritation as a result of infection, interstitial cystitis, 
calculi, and bladder hypersensitivity.22
The NBC index is a complicated formula that ad-
dresses voiding at night in patients with a decreased 
NBC. The NBC index is the actual number of nightly voids 
minus the predicted number of nightly voids. An NBC 
index of > 2 may result from prostatic obstruction, noc-
turnal detrusor overactivity, a neurogenic bladder, a 
primary bladder pathology such as cancer (bladder, 
prostate, or urethra), learned voiding dysfunction, anxi-
ety disorders, certain pharmacological agents, or blad-
der and ureteral calculi.23
4.4. Mixed nocturia
Many patients with nocturia have a combination of noc-
turnal polyuria and a lower NBC. The relative roles of 
these factors may differ between sexes. It has been re-
ported that male nocturia is more often related to noc-
turnal polyuria, whereas female nocturia is more often 
related to a small bladder capacity.24 The relative roles 
of the various factors may also differ between ethnic 
groups.25
Mixed nocturia should be diagnosed through the 
maintenance and analysis of bladder diaries.
5. Treatment
The large range of causes of nocturia suggests that the 
same treatment strategy is unlikely to work in all patients. 
The logical first step to approach nocturia treatment 
should be to eliminate underlying causes. If nocturia 
appears to be due to a non-urological disease such as 
congestive heart failure, poorly controlled diabetes, or 
obstructive sleep apnea, these underlying conditions 
should be treated as a priority.
Obese individuals may have increased nocturnal pro-
duction of urine as a result of increased fluid intake 
before bedtime, and AVP sensitivity is also impaired in 
obese individuals. Abdominal obesity can increase intra-
abdominal pressure and cause nocturia. These findings 
suggest that the relationship between obesity and nocturia 
is unidirectional; obesity increases the risk of nocturia.26
Changes in lifestyle and behavior might also be effec-
tive in selective patients with nocturia. If a patient his-
tory indicates that nocturia is due to excessive fluid 
intake, particularly caffeinated or alcoholic beverages, 
then restrictions on caffeine, alcohol, and fluid con-
sumption may help alleviate the disorder.2 One recent 
study demonstrated the effect of modification of fluid 
intake on nocturia.27 In contrast, Shiri et al.26 found no 
significant association between coffee consumption and 
nocturia.
However some data suggest that this method alone 
might not be ideal for improving nocturia in the elderly. 
Asplund and Aberg28 found that nearly half of elderly 
patients who woke more than three times a night to uri-
nate had already restricted their fluid intake in the 
evening. Fluid restriction only before bedtime is rarely 
effective if nocturia is the result of gravity-induced third 
spacing of fluid in the lower extremities. Diuretics given 
during the late afternoon or early evening may help 
decrease the third spacing of fluid. Compression stock-
ings and afternoon leg elevation may combat fluid re-
tention in the legs and help diminish nocturnal urinary 
output.
Any factors that adversely influence nighttime sleep 
should be addressed and eliminated. However, lifestyle 
and behavioral changes are rarely effective alone, ne-
cessitating pharmacotherapy in most nocturia patients.
6. Pharmacology
6.1. Desmopressin acetate
If nocturia is due to nocturnal polyuria but is not explained 
by underlying diseases, lifestyle factors, or medications, 
inadequate AVP secretion or disturbed AVP function can 
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be assumed. Treatment with AVP analogs appears justi-
fied under such conditions. Desmopressin acetate is a 
synthetic analog of AVP that has been used for several 
decades to treat DI and nocturnal enuresis and is availa-
ble in nasal, oral, and parenteral formulations. Early stud-
ies mostly used a desmopressin dose of 20 μg given either 
orally or intranasally.29–31 The populations in those studies 
tended to be very small (fewer than 25 patients), but in 
later studies they were considerably larger with higher 
applied oral doses (0.1–0.4 mg) with 3 weeks of double-
blind treatment.32,33
The efficacy of desmopressin in treating nocturia has 
been examined in various populations, including men, 
women, and the elderly, in both short- and long-term 
studies.32,34,35 QoL analyses have also indicated greater 
improvement in terms of prevalence, annoyance, and 
problems caused by nocturia, in patients treated with 
desmopressin compared with placebos.35 Desmopressin 
increases the length of time until the first nocturnal 
void, lowers the number of nocturnal voids, and de-
creases the percentage of urine voided at night.35
Treatment of nocturia in elderly patients with 
desmopressin should only be undertaken together with 
careful monitoring of serum sodium concentrations. 
A significant fall in serum sodium concentration can occur 
within 72 hours, and the risk rises with increasing age 
(over 65-year-old group being most at risk).36 In patients 
at risk of hyponatremia, the sodium concentration 
should be checked within 1 week, and the dose should 
be titrated. For long-term desmopressin administration, 
the serum sodium concentration should be carefully 
assessed for at least 6 months.37
6.2. Antimuscarinic agents
Muscarinic receptor antagonists are the mainstay of 
medical treatment for an overactive bladder. These 
agents are believed to exert their effects by directly in-
hibiting the muscarinic receptors within the detrusor 
muscle, which leads to bladder contraction and void-
ing.38 Recent reviews have suggested that in addition to 
this mechanism, antimuscarinics also function via affer-
ent pathways, alleviating the sensation of urgency.39,40 
Their effect on nocturia was also evaluated in a series of 
12-week double-blind studies including darifenacin,41,42 
solifenacin,43,44 tolterodine,45,46 and trospium.47
In a double-blind trial comparing solifenacin with tol-
terodine in patients with an overactive bladder, both 
were observed to be effective in reducing nocturia epi-
sodes (a reduction of 0.71 and 0.63 episodes, respec-
tively).48 However, this study lacked a placebo arm, 
which limits its validity because the extent of improve-
ment attributable to the placebo effect could not be 
determined.
Improvements in nocturia have typically been only 
moderate and do not consistently reach statistical sig-
nificance across all studies of a given drug. A recent 
study showed that a combination of a muscarinic antag-
onist (tolterodine) and an alpha blocker (tamsulosin) 
caused a greater, although still only moderate, improve-
ment in nocturia than either agent alone.49
The available antimuscarinic agents have different 
physicochemical and pharmacokinetic properties that may 
impact their safety and tolerability in certain popula-
tions. Oxybutynin, solifenacin, tolterodine, and darifenacin 
are tertiary amines, which have the potential to cross 
the blood-brain barrier.50 The blockade of central mus-
carinic receptors may cause adverse central nervous 
system effects, including cognitive dysfunction, halluci-
nations, and confusion. A new quaternary amine anti-
muscarinic agent, trospium, is hydrophilic and lipophobic, 
resulting in a low possibility of crossing the blood-brain 
barrier and causing adverse effects.51 Because nocturnal 
production of hormones is impaired in some nocturia 
adults, administration of melatonin can restore a normal 
circadian rhythm of micturition and improve sleep. 
It was reported that men treated with 2 mg of melatonin 
generally experienced a 10% reduction in episodes of 
nocturia.52
Alpha1-adrenoceptor antagonists and 5α-reductase 
inhibitors are also used in men with symptoms indica-
tive of benign prostate hyperplasia, and one of their 
effects is a reduction in nocturia. On the other hand, in 
women, estrogen deficiency, a common consequence 
of the menopausal transition, causes atrophic changes 
within the urogenital tract. Consequently, such women 
are more disposed to having urogenital symptoms, 
among which is nocturia.53
7. Surgery
Transurethral resection or incision of the prostate 
may be appropriate when obstruction related to the 
prostate is the main causative factor of nocturia. 
Treatment options for selective nocturia patients in-
clude pelvic reconstructive surgery for organ prolapse, 
detrusor myomectomy and cystoplasty for decreased 
bladder capacity, and botulinum toxin detrusor injection 
for neurogenic and idiopathic detrusor overactivity.54
A mini-invasive surgical technique for urgency, urge 
incontinence, and nocturia is sacral neuromodulation. 
Although evidence of its efficacy is preliminary, the pro-
cedure has been successfully used for reducing the 
degree of urgency and total number of voids.55
8. Conclusions
The pathophysiology of nocturia is multifactorial and 
can be complex. Its cause remains unclear in a signifi-
cant number of patients. The ICS defines nocturia as, 
“the complaint that the individual has to wake at night 
one or more times to void”.2
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In general, the inconvenience associated with noctu-
ria occurring once is limited, whereas nocturia occurring 
twice or more is highly disruptive. Bladder diaries are 
necessary to make a differential diagnosis of the etiol-
ogy of a subject’s nocturia. Treatment should be tailored 
to the condition causing the nocturia. If nocturia ap-
pears to be due to non-urological diseases, such as con-
gestive heart failure, poorly controlled diabetes, or 
obstructive sleep apnea, the underlying condition 
should be treated as a priority. Changes in lifestyle and 
behavior can be effective in selective patients with noc-
turia, but pharmacological treatment is often required. 
Desmopressin, antimuscarinic agents, and α1-blockers 
are modestly effective compared with placebos. Cor-
rectly diagnosing and treating nocturia, especially in eld-
erly patients, will improve the patients’ sleep and, in turn, 
reduce their risk of fall injuries and the associated detri-
mental consequences, thereby improving the patients’ 
health and QoL.
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